Galderma Canada Inc. today announced the Health Canada approval of Rosiver (ivermectin) cream 1%, a once-daily topical treatment for inflammatory lesions (papules and pustules) of rosacea in adults 18 years of age or older.  Rosacea is a common skin condition that affects more than two million Canadians. It often presents as a redness, like a blush, appearing on the face, but may gradually appear on the ears, chest, back, and eyes.  Although the cause of rosacea is unknown, research suggests that there are multiple triggers for the inflammation associated with the condition, including sun, alcohol, spicy food and exercise.  Recent studies have further solidified that generally harmless microscopic Demodex mites may also be a culprit. These mites are normal inhabitants of everyone's skin, but may appear in greater numbers on the faces of people with rosacea.

"Rosacea is a condition that has a dramatic impact on patients, although it is not something that is physically life threatening, it can present a significant emotional toll," says Dr. Melinda Gooderham, Dermatologist and Medical Director at the SKiN Centre for Dermatology in Peterborough, Ontario.  "The approval of Rosiver and its novel approach is another promising step for Canadian patients who are looking for new and effective options to manage these challenging symptoms."

For more details, go to: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=121983#.Va4213jC1Vs